(Q38872315)

7 September 2017

title

A hepatitis B vaccine formulated with a novel adjuvant system (English)

1 reference

7 September 2017

1 reference

1 reference

1 reference

M Kundi

1 reference

7 September 2017

M Slaoui

1 reference

7 September 2017

F Ambrosch

1 reference

7 September 2017

G Wiedermann

1 reference

7 September 2017

G Leroux-Roels

1 reference

7 September 2017

I Desombere

1 reference

7 September 2017

N Garcon

1 reference

7 September 2017

C Thiriart

1 reference

7 September 2017

S Thoelen

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

2095-2101

1 reference

Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Hepatitis in travellers: epidemiology and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Response to hepatitis B vaccine: multiple HLA genes are involved

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences 2. Immunogenicity in poor responders to hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Inactivated hepatitis A vaccine: long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

[Persistence of antibodies against hepatitis B surface antigens after vaccination against hepatitis B]

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Immunologic Prevention of Human Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Hepatitis B vaccination: protection for how long and against what?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

Hepatitis B vaccine boosting: the debate continues

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900566-6

7 January 2021

10.1016/S0264-410X(99)00566-6

Identifiers

DOI

1 reference

7 September 2017

1 reference